Dr. Michelle A. Petri, MD

Dr. Petri practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Petri's NPI, 1548206683, was assigned on June 20, 2006. Dr. Petri graduated from Harvard Medical School in 1980. Dr. Petri holds Maryland license D33659.

Dr. Petri's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Petri's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Petri is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Petri to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Petri practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Petri's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Petri is licensed in Maryland.

CMS data shows 866 Medicare services from Dr. Petri across 3 procedure codes in 2024, for 246 Medicare patients. Medicare paid $40,456 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 246 Medicare patients who saw Dr. Petri in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Petri's median patient age at 66, with 90% women.

In 2024, Dr. Petri wrote 1,801 Medicare Part D claims for 209 patients. 95% of them were for generic drugs. CMS names the drug for 1,513 of them, across 26 drugs with 11 or more claims each, at $149,365 in total drug cost. In 2023, CMS named 1,469 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Petri for performance year 2024, reported as part of a group.

Dmand AI links 199 papers to Dr. Petri, published from 2016 to 2025. 2019 was the busiest year, with 35. The most frequent topics are Lupus Erythematosus, Systemic, Lupus Nephritis and Antiphospholipid Syndrome. Dr. Petri has published most often in Lupus Sci Med. Dr. Petri's most frequent co-authors are Daniel J. Wallace, MD, Kenneth Carekin Kalunian, MD and Diane Leigh Kamen, MD.

Dmand AI links Dr. Petri to 2 clinical trials. Conditions studied include Anthrax, Arthritis, Rheumatoid and Bacillaceae Infections. Open Payments lists research payments to Dr. Petri that name 2 trials.

CMS Open Payments shows 357 general payments to Dr. Petri from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. AstraZeneca Pharmaceuticals LP paid the most, $83,784. It also lists 33 research payments totaling $26,718 from 2016 to 2025, naming 2 clinical trials.

Dr. Petri graduated from Harvard Medical School in 1980.